



**Novartis India Limited**  
Registered Office:  
Sandoz House  
Shivsagar Estate  
Dr. Annie Besant Road  
Worli, Mumbai 400 018  
India  
Tel +91 22 2495 8400  
Fax +91 22 2495 0221  
Email: [india.investors@novartis.com](mailto:india.investors@novartis.com)  
CIN No. L24200MH1947PLC006104  
Website: [www.novartis.in](http://www.novartis.in)

May 10, 2018

The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001.

**Outcome of the Board Meeting**

Dear Sirs,

We refer to our letter dated March 29, 2018, informing you of our Board Meeting that was scheduled for today. Please note that the Board of Directors of Novartis India Limited met today at 3.30 p.m. and the meeting concluded at 7.00 p.m.

The following items were considered and approved:

1. Appointment of Mr. Milan Paleja as the Vice Chairman & Managing Director of the Company with effect from June 1, 2018. A brief profile of Mr. Milan Paleja along with the press release is enclosed for your information;
2. Audited Financial Results of the Company for the year ended March 31, 2018;
3. Recommendation of final dividend of Rs 10/- per equity share of Rs 5/- each for the year ended March 31, 2018;
4. Convening of the 70<sup>th</sup> Annual General Meeting of shareholders of the Company on Friday, July 27, 2018 at 11.30 a.m.;
5. Closure of the Register of Members and Share Transfer books from Friday, July 20, 2018 to Friday, July 27, 2018, both days inclusive, for determining the eligibility of shareholders for payment of Dividend.
6. Recommendation for re-appointment of the Statutory Auditors, M/s. Deloitte Haskins and Sells LLP (Firm Registration No. 117366W/W-100018) from the conclusion of the 70<sup>th</sup> Annual General Meeting to the conclusion of 71<sup>st</sup> Annual General Meeting of the Company, subject to the approval of the shareholders of the Company.

We have made arrangements for publishing an extract of the approved financial results as per the format prescribed under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, in the selected newspapers.

Please take the same on record.

Thanking You.

For **Novartis India Limited**



**Trivikram Guda**  
**Company Secretary &**  
**Compliance Officer**

*Encl: As above*

**MEDIA RELEASE • MEDIA RELEASE • MEDIA RELEASE****Novartis India Limited reconstitutes Board; appoints Milan Paleja as Vice Chairman & Managing Director**

**Mumbai, May 10, 2018** – At a meeting held in Mumbai today, the Board of Directors of Novartis India Limited announced the appointment of Milan Paleja as Vice Chairman & Managing Director effective June 01, 2018.

Milan Paleja is Country President, Novartis in India and also responsible for the pharmaceuticals business in the country. He is also a Managing Director of Novartis Healthcare Private Limited.

Milan Paleja joined Sandoz India in 1982 in the Finance function. He has gained a wealth of experience over the years having held positions of increasing responsibility in Consumer Health, Sandoz and Pharmaceuticals, at country and regional level, in diverse geographies such as Singapore, South Africa and Switzerland. Since March 2016, he was Country President and Head Pharmaceuticals, Novartis Indonesia. While in Indonesia, he pioneered innovative access models, turned around the business and laid the foundation for future growth.

Mr. Paleja is a graduate from Bombay University and holds a Cost Accountants degree from the Institute of Cost Accountants of India.

**Novartis India Media Relations**

Svetlana Pinto  
+91 22 2495 1074 (direct)  
+91 98210 54884 (mobile)  
[svetlana.pinto@novartis.com](mailto:svetlana.pinto@novartis.com)

Liana Albuquerque  
+91 22 2495 8805 (direct)  
+91 98214 36458 (mobile)  
[liana.albuquerque@novartis.com](mailto:liana.albuquerque@novartis.com)